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Abstract
Introduction: This report presents the clinical and laboratory course of a patient with prostate
cancer and severe vitamin B12 deficiency undergoing watchful waiting for prostate cancer. The
possible interaction between therapy for B12 deficiency and the natural course of prostate cancer
is presented.
Case presentation: We present the case of a 75-year-old Chinese man with prostate cancer and
pernicious anemia. His serum vitamin B12  level was 32 pg/ml (300-900 pg/ml) and
holotranscobalamin was 0 pg/ml (>70 pg/ml). There was an unexpected rapid progression of
Gleason's score during 10 months of watchful waiting. After the diagnosis of pernicious anemia was
made, therapeutic injections of vitamin B12 were started. We observed a significant acceleration in
prostate-specific antigen and prostatic acid phosphatase and a shortening of prostate-specific
antigen doubling time after initiation of B12 therapy.
Conclusion: We propose that the relatively short period of watchful waiting before histological
progression of Gleason's score (GS [3+2] = 5 to GS [3+4] = 7 over 10 months) may have been a
result of depleted holotranscobalamin 'active' B12. Replacement of B12 was associated with an initial
rapid increase in serum prostate-specific antigen and prostatic acid phosphatase followed by
stabilization. The patient represents an 'experiment of nature' involving vitamin B12 metabolism and
raises the question as to whether rapid histological progression of Gleason's score was related to
absence of serum holotranscobalamin while prostate-specific antigen and prostatic acid
phosphatase, markers of cell growth, were accelerated by vitamin B12 replacement. To our
knowledge, this is the first report of a possible cellular kinetic interaction between an epithelial
malignancy and vitamin B12 metabolism.
Introduction
Twenty percent of serum vitamin B12 is bound to a protein
as holotranscobalamin (holoTC, 'active' B12) while 80% is
bound to a glycoprotein as holohaptocorrin. B12 bound as
holohaptocorrin is metabolically inert but represents the
majority of measurable total serum B12. The most com-
mon cause of depressed holotranscobalamin is age-
related gastric atrophy with hypochlorhydria leading to
malabsorption of protein-bound B12. It is only rarely that
patients present with classical pernicious anemia with the
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failure to secrete intrinsic factor. Our laboratory has previ-
ously reported on the frequency of depressed levels of hol-
otranscobalamin in newly diagnosed patients with a
variety of cancer types, including prostate cancer, and
observed approximately 33% of all cancer patients (17/
52) to be holotranscobalamin-insufficient before therapy
[1]. In the same study, 5 out of 15 prostate cancer patients
possessed deficient levels of holotranscobalamin [1]. B12
plays a critical role in DNA synthesis and one-carbon
transfer reactions mediated through S-adenosylmethio-
nine. B12 insufficiency may lead to decreased DNA meth-
ylation, which is associated with interference of histone
metabolism and genetic mutation [2-4].
Pernicious anemia (PA) is associated with an increased
rate of secondary malignancies, which include cancer of
the stomach (standardized incident rate (SIR) = 2.9),
esophagus (SIR = 3.2), and pancreas (SIR = 1.7) among
men and women; myeloid leukemia among men (SIR =
1.8-5.2); and multiple myeloma among women (SIR =
2.5) [5]. An elevated incidence of secondary gastric carci-
noid tumors was also reported. The risk of stomach cancer
was highest in the first year after diagnosis of pernicious
anemia (SIR = 7.4), but an increased risk persisted
throughout life.
That vitamin B12 may accelerate normal and cancer cell
proliferation within the milieu of B12 insufficiency may be
observed in tissue culture for L1210 mouse leukemia cells
grown in a B12 deficient medium [6] as well as in the clinic
[7]. The administration of parenteral B12 in pancytopenic
patients with B12 deficiency is associated with a brisk
hematopoietic response. In such patients, associated epi-
thelial cell dysplasias (bronchial, esophageal, buccal and
cervical) return towards normal [8]. In one study of 51
patients with bronchial metaplasia, 77% of the control
group remained stable while 90% of patients treated with
folate and B12 decreased in metaplasia scoring, which
demonstrated a reversal of metaplasia [9]. Additionally,
Corsino  et al. demonstrated kinetic control of chronic
myelogenous leukemia cells in response to parenteral
replacement of B12 in a patient with both pernicious ane-
mia and chronic granulocytic leukemia [7]. They
described this in their paper as 'an experiment of nature'.
Cognizant of the role B12 played in dysplasia and normal
and cancer cell kinetics, we closely monitored potential
modulator effects of B12 replacement therapy in a patient
presenting with prostate cancer and advanced B12 deple-
tion whose clinical course of watchful waiting had been
remarkably short.
Case presentation
A 75-year-old Chinese man presented to his urologist with
prostate-specific antigen (PSA) = 4 and this was followed
by core needle biopsy. The diagnosis of clinical T1c,
Gleason's score (GS) = [3+2] = 5 adenocarcinoma of the
prostate was made. One of six cores (5% of the length)
contained adenocarcinoma and two of six cores contained
grade III prostatic intraepithelial neoplasia (PIN). The
patient elected to undergo no further therapy other than
observation. Unfortunately, a baseline complete blood
count (CBC) was not obtained at the time of prostate
biopsy on 18 October 2007. A hemoglobin (Hb) level of
13.7 g/dl and a mean corpuscular volume (MCV) of 99 fl
were recorded on the 19 August 2005. Over the next 10
months, he had no urological complaints; however,
repeat PSA measurements revealed rapidly progressive
disease with an increase in his PSA from 4.0 to 16.7 ng/ml
and a decrease in prostate-specific antigen doubling time
(PSADT) from 10.5 to 5.3 months.
The patient's urologist repeated the prostate biopsy on 23
August 2008 and noted clinical progression from T1c to
T2b disease. The biopsy revealed 4 of 6 cores positive for
GS = [3+4] = 7 with 25% of the submitted material con-
taining cancer.
The patient presented to our office and was noted to be
anemic, but with no specific complaints of tiredness. Ane-
mia work-up revealed Hb at 7.5 g/dl and MCV at 124 fl.
There was macro-ovalocytosis, hypersegmentation of neu-
trophils, and a single six lobe neutrophil on a Wright's
Giemsa stained blood smear. The serum level of total B12
was 32 pg/ml (= 300 pg/ml), holoTC was 0 pg/ml (>70
pg/ml), serum methylmalonic acid (MMA) was 13,970
nM/l (87-318 nM/l), total homocysteine (tHcy) was
108.8 μM/l (<12 μM/l), reticulocyte count was depressed
to 9500 cells/μl (25,000-90,000 cells/μl) and haptoglobin
was <6 mg/dl (43-212 mg/dl). Blocking antibody to
intrinsic factor was present. A diagnosis of B12 deficiency
due to presumed atrophic gastritis and classical pernicious
anemia was made. Iron deficiency was ruled out by virtue
of normal levels for serum iron/total iron binding capac-
ity (TIBC), % saturation of TIBC, ferritin, and red cell zinc
protoporphyrin. Serum folic acid was 17.4 ng/ml (=5).
Other causes of anemia were excluded through a negative
Coomb's test and normal renal function as manifested by
normal serum cystatin-c and serum creatinine. Thyroid
antibody studies plus serum thyroid stimulating hormone
(TSH) and free T4 were normal. There were no neurologi-
cal findings, proprioception of the toes and vibratory sen-
sation of the toes to a 256 vps tuning fork were intact.
Diagnoses of laboratory, clinical and histological progres-
sion of prostate cancer in addition to profound pernicious
anemia were confirmed.
All PSA and prostatic acid phosphatase (PAP) measure-
ments were made with the same in-house DPC Immulite®
assay with sensitivity to 0.003 ng/ml, standard error ofJournal of Medical Case Reports 2009, 3:9295 http://www.jmedicalcasereports.com/content/3/1/9295
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0.003 ng/ml and coefficient of variation (CV) <4%. The
patient was started on subcutaneous B12  injections as
cyanocobalamin 1000 μg daily while measurements for
methylmalonic acid, total homocysteine, reticulocyte
count, Hb, PSA, PSADT, PSA velocity (PSAV), and PAP,
were recorded at frequent intervals (Table 1 and Figures 1
and 2). The patient did not receive supplemental folic
acid; however, he was given an oral preparation of potas-
sium chloride 20mEq daily anticipating a possible intrac-
ellular potassium shift in response to B12 administration.
The patient had a hematological response to B12 replace-
ment. Following B12 supplementation, we recorded a
rapid increase in serum PSA from 16.7 to 22.9 ng/ml over
just a 9-day period and PAP increased from 1.5 ng/ml to
2.3 ng/ml and ultimately to 3.2 ng/ml (<3.0 ng/ml) 20
days after the initiation of B12 (Table 1 and Figures 1, 2,
3, and 4). Twenty days after initiation of B12, PSA and
PAP levels stabilized at 21.1 ng/ml and 3.2 ng/ml, respec-
tively (Table 1). After 34 days of daily B12 injections, PSA
was 21.3 ng/ml and PAP was 2.4 ng/ml (Table 1). PSAV
was noted to have rapidly increased from 19.7 ng/ml/year
to 251 ng/ml/year while PSADT decreased from 5 months
to 0.65 months.
Discussion
We conjecture that this patient's accelerated prostatic his-
tological and clinical progression during watchful waiting
could have been modulated by the concomitant profound
deficiency of B12 in light of the central role played by B12
in DNA synthesis, association with worsening of epithe-
lial dysplasia and induction of genetic mutations. Data
from studies by Choo and colleagues reveal that the usual
rate of histological progression for watchful waiting is
2.4% of patients at a median of 29 months of observation
[10,11]. Histological progression is generally limited to
one higher Gleason's grade [10,11]. Our case progressed
two Gleason's grades within 10 months while clinical
stage advanced from T1c to T2b.
The same expert pathologist ascertained the Gleason score
progression through a side-by-side comparison of the first
biopsy with the second. Furthermore, it should be noted
that 78% of the time, intrapathological review is precisely
reproducible and 87% of the time reproducible within +1
Gleason score [12]. However, there is always the possibil-
ity that a needle sampling variation of cancer tissue could
have accounted for the apparent histological progression.
However, the rapid change of clinical stage (T1c to T2b),
the increase in number to positive cores (1 of 6 to 4 of 6)
and the accelerated PSA and PAP kinetics suggest there
could be a B12 prostate cancer interaction.
At the same time, a rapid rise in both PSA and PAP, accel-
eration of PSAV and shortening of PSADT rapidly fol-
lowed supplementation of B12. These changes suggest that
absence of holoTC, the active component of serum B12,
may have in part retarded prostate cancer growth while at
the same time possibly participating in generation of
mutations associated with rapid histological progression.
Table 1: Clinical laboratory data
18 October 
2007 - 
Diagnosis 
prostate 
cancer
19 February 
2008 - PSA 
progression
4 June 2008 
- PSA 
progression
21 October 
2008 - 
Diagnosis of 
PA
30 October 
2008 - B12 Rx
10 November 
2008 - B12 Rx
24 November 
2008 - B12 Rx
Hb, g/dl - - - 7.5 8.6 9.2 9.9
MCV, fl - - - 124 122 117.7 113
Reticulocyte count, 
cells/μl
- - - 9500 23,230 11,450 7470
MMA, nM/l - - - 13,970 3069 - 290
tHcy, μM/l - - - 109 14 18.8 14.8
B12, pg/ml - - - 32 >1500 >1500 >1500
holoTC, pg/ml - - - 0 - - -
Testosterone, ng/dl - - - 331 346 205 323
PSA, ng/ml 4.0 7.3 9.2 16.7 22.9 21.1 21.3
PAP, ng/ml - - - 1.5 2.3 3.2 2.4
Folate, ng/ml - - - 17.4 - 17.5 -
B12 injection, μg/
day subcutaneous
- - - 1000 1000 1000 1000
B12, cobalamin; Hb, haemoglobin; holoTC, holotranscobalamin; MMA, methylmalonic acid; PA, pernicious anemia; PAP, prostatic acid phosphatase; 
PSA, prostate specific antigen; Rx, treatment; tHcy, total homocysteine.Journal of Medical Case Reports 2009, 3:9295 http://www.jmedicalcasereports.com/content/3/1/9295
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Conclusion
We recommend that all patients opting to pursue watch-
ful waiting for prostate cancer undergo an initial serum
B12 assay, including serum holoTC. HoloTC is depleted
before total B12  falls within the abnormal range [1].
Although our findings are preliminary and based on only
a single case report, monitoring a patient's B12 and holoTC
remain important due to the prevalence of B12 and hol-
oTC insufficiency in elderly individuals for whom watch-
ful waiting is frequently implemented [1]. If B12
insufficiency is present then it should be corrected imme-
diately. The AxSYM® Active-B12 holotranscobalamin via
the Abbott AxSYM immunoassay is the only Food and
Drug Administration approved assay for holoTC in the
USA. Glass adsorption assay is another technique (devel-
oped in this laboratory [13] as a modification of that first
described by Victor Herbert).
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